Development and validation of a spectrophotometric assay for measuring the activity of NADH: Cytochrome b5 reductase in human tumour cells

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1188-1193

  Barham, H M ^a   Inglis, R ^a   Chinje, E C ^a,b   Stratford, I J ^a,b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bioreductive drug; DT diaphorase; Hypoxia; N oxide; Reductive activation

Indexed keywords

CYTOCHROME B5 REDUCTASE; CYTOCHROME C; ENZYME INHIBITOR; HYDROXYMERCURIBENZOIC ACID;

ANALYTIC METHOD; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; REDUCTION; SPECTROPHOTOMETRY; TUMOR CELL;

EID: 0029804277     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.515     Document Type: Article

References (25)

1. BARHAM HM. (1993). An evaluation of the female DA rat as a model of the human CYP2D6 poor metabolizer phenotype. PhD thesis, University of Sheffield, UK.
2. 5 reductase. Biochem. Pharmacol., 51, 829-837.
3. CHOURY D, LEROUX A AND KAPLAN JC. (1981). Membrane-bound cytochrome b5 reductase (methemoglobin reductase) in human erythrocytes. Study in normal and methemoglobinemic subjects. J. Clin, Invest., 67, 149-155.
4. ERNSTER L, DANIELSON L AND LJUNGGREN M. (1962). DT Diaphorase: I. Purification from the soluble fraction of rat liver cytoplasm, and properties. Biochim. Biophys. Acta, 58, 171-188.
5. GHESQUIER D, ROBERT JC, SOUMARMON A, ABASTADO M, GRELAC F AND LEWIN MJM. (1985). Gastric microsomal NADH-cytochrome b5 reductase: characterisation and solubilization. Camp. Biochem. Physiol., 80B, 165-169.
6. GÜRAY T AND ARINC E. (1991). Purification of NADH-cytochrome b5 reductase from sheep lung and its electrophoretic, spectral and some other properties. Int. J. Biochem., 23, 1315-1320.
7. HODNICK WF AND SARTORELLI AC. (1993). Reductive activation of mitomycin C by NADH: cytochrome b5 reductase. Cancer Res., 53, 4907-4912.
8. HODNICK WF AND SARTORELLI AC. (1994). The pH-dependent reduction of adriamycin catalysed by NADH:cytochrome b5 reductase. Cancer Lett., 84, 149 - 154.
9. HOULBROOK S, KIRK J, STUART NSA, STRATFORD IJ, HARRIS AL, PETTIT GR AND CARMICHAEL J. (1994). Human tumour cell lines: a valuable model for the evaluation of mechanisms underlying cytotoxic drug resistance. Oncology (Life Sci. Adv.), 13, 69-76.
10. LEROUX A, TORLINSKI L AND KAPLAN JC. (1977). Soluble and microsomal forms of NADH:cytochrome b5 reductase from human placenta. Similarity with NADH-methemoglobin reductase from human erythrocytes. Biochim. Biophys. Acta, 481, 50-62.
11. LOSTANLEN D, VIEIRA DE BARROS A. LEROUX A AND KAPLAN JC. (1987). Soluble NADH:cytochrome b5 reductase from rabbit liver cytosol: partial purification and characterisation. Biochim. Biophys. Acta, 526, 42-51.
12. PASSON PG AND HULTQUlST DE. (1972). Soluble cytochrome b5 from human erythrocytes. Biochim. Biophys. Acta, 275, 62-73.
13. PATTERSON AV, BARHAM HM, CHINJE EC. ADAMS GE, HARRIS AL AND STRATFORD IJ. (1995). Importance of P450 reductase activity in breast tumour cell for determining sensitivity to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer, 72, 1144-1150.
14. PHILLIPS AH AND LANGDON RG. (1962). Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization and kinetic studies. J. Biol. Chem., 237, 2652-2660.
15. PLUMB JA, GERRITSEN M AND WORKMAN P. (1994). DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinione E09. Br. J. Cancer, 70, 1136-1143.
16. RILEY RJ AND WORKMAN P. (1992). Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem. Pharmacol., 43, 1657-1669.
17. ROBERTSON N, HAIGH A, ADAMS GE AND STRATFORD IJ. (1994). Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase and hypoxia. Eur. J. Cancer, 30A, 1013-1019.
18. SEGURA-AGUILAR J. CORTES-VIZCAINO V, LLOMBART-BOSCH A. ERNSTER L. MONSALVE E AND ROMERO FJ (1990). The levels of quinone reductases, superoxide dismutase and glutathione-related enzymatic activities in diethyl stilbestrol-induced carcino-genesis in the kidney of male Syrian golden hamsters. Carcinogenesis. 11, 1727- 1732.
19. SMITH PK, KROHN RI, HERMANSON GT, MALLIA AK, GARTNER FH. PROVENZANO MD, FUJIMOTO EK. GROEKE NM. OLAON BJ AND KLENK DC. (1985). Measurement of protein using bicinchoninic acid. Anal. Biochem., 150, 76-85.
20. SOTTOCASA GL, KUYLENSTIERNA B. ERNSTER L AND BERGSTRAND A. (1967). An electron transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J. Cell Biol., 32, 415-438.
21. TAMURA M, YUBISUI T AND TAKESHlTA M. (1988). The opposite effect of bivalent cations on cytochrome b5 reduction by NADH:cytochrome b5 reductase and NADPH:cytochrome c reductase. Biochem. J., 251, 711-715.
22. 2 tension measurements. Cancer Res., 51, 3316-3322.
23. WILLIAMS CH JR AND KAMIN H. (1962). Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J. Biol. Chem., 237, 587-595.
24. WORKMAN AND STRATFORD IJ. (1993). The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast. Rev., 12, 73-82.
25. WORKMAN P AND WALTON MI. (1989). Enzyme-directed bioreductive drug development. In Selective Activation of Drugs by Redox Processes, Adams GE, Breccia A, Fielden EM and Wordman P. (eds) pp. 89- 112, Plenum Press: New York.